Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 2
1959 1
1961 7
1962 5
1963 5
1964 10
1965 4
1966 8
1967 10
1968 10
1969 10
1970 15
1971 24
1972 22
1973 19
1974 42
1975 33
1976 26
1977 28
1978 40
1979 34
1980 31
1981 47
1982 53
1983 74
1984 77
1985 85
1986 103
1987 99
1988 86
1989 111
1990 129
1991 108
1992 121
1993 92
1994 108
1995 113
1996 128
1997 138
1998 166
1999 143
2000 165
2001 190
2002 173
2003 166
2004 179
2005 207
2006 179
2007 180
2008 192
2009 197
2010 194
2011 220
2012 229
2013 241
2014 241
2015 236
2016 228
2017 244
2018 271
2019 288
2020 279
2021 354
2022 350
2023 332
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

7,328 results

Results by year

Filters applied: . Clear all
Page 1
Blocking PD-L1-PD-1 improves senescence surveillance and ageing phenotypes.
Wang TW, Johmura Y, Suzuki N, Omori S, Migita T, Yamaguchi K, Hatakeyama S, Yamazaki S, Shimizu E, Imoto S, Furukawa Y, Yoshimura A, Nakanishi M. Wang TW, et al. Among authors: yamaguchi k. Nature. 2022 Nov;611(7935):358-364. doi: 10.1038/s41586-022-05388-4. Epub 2022 Nov 2. Nature. 2022. PMID: 36323784
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY. Shitara K, et al. Among authors: yamaguchi k. Nature. 2022 Mar;603(7903):942-948. doi: 10.1038/s41586-022-04508-4. Epub 2022 Mar 23. Nature. 2022. PMID: 35322232 Free PMC article. Clinical Trial.
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.
Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Borg C, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Collins H, Mitra S, Yang Y, Catenacci DVT, Lee KW. Wainberg ZA, et al. Among authors: yamaguchi k. Lancet Oncol. 2022 Nov;23(11):1430-1440. doi: 10.1016/S1470-2045(22)00603-9. Epub 2022 Oct 14. Lancet Oncol. 2022. PMID: 36244398 Clinical Trial.
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J; Japan Clinical Oncology Group (JCOG). Morizane C, et al. Among authors: yamaguchi k. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. doi: 10.1001/jamaoncol.2022.3395. JAMA Oncol. 2022. PMID: 35980649 Free PMC article. Clinical Trial.
Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial.
Nishiyama Y, Kimura K, Otsuka T, Toyoda K, Uchiyama S, Hoshino H, Sakai N, Okada Y, Origasa H, Naritomi H, Houkin K, Yamaguchi K, Minematsu K, Matsumoto M, Tominaga T, Tomimoto H, Terayama Y, Yasuda S, Yamaguchi T; CSPS.com Trial Investigators. Nishiyama Y, et al. Among authors: yamaguchi k. Stroke. 2023 Mar;54(3):697-705. doi: 10.1161/STROKEAHA.122.039900. Epub 2023 Feb 3. Stroke. 2023. PMID: 36734235 Clinical Trial.
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
Yamaguchi K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Shimoyama T, Lee KW, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Shitara K. Yamaguchi K, et al. J Clin Oncol. 2023 Feb 1;41(4):816-825. doi: 10.1200/JCO.22.00575. Epub 2022 Nov 15. J Clin Oncol. 2023. PMID: 36379002 Free PMC article. Clinical Trial.
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.
Yoshino T, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Wainberg Z, Elez E, Rodriguez J, Fakih M, Ciardiello F, Saxena K, Kobayashi K, Bako E, Okuda Y, Meinhardt G, Grothey A, Siena S; DESTINY-CRC01 investigators. Yoshino T, et al. Among authors: yamaguchi k. Nat Commun. 2023 Jun 7;14(1):3332. doi: 10.1038/s41467-023-38032-4. Nat Commun. 2023. PMID: 37286557 Free PMC article.
Phosphatidylinositol-3,4,5-trisphosphate interacts with alpha-synuclein and initiates its aggregation and formation of Parkinson's disease-related fibril polymorphism.
Choong CJ, Aguirre C, Kakuda K, Beck G, Nakanishi H, Kimura Y, Shimma S, Nabekura K, Hideshima M, Doi J, Yamaguchi K, Nakajima K, Wadayama T, Hayakawa H, Baba K, Ogawa K, Takeuchi T, Badawy SMM, Murayama S, Nagano S, Goto Y, Miyanoiri Y, Nagai Y, Mochizuki H, Ikenaka K. Choong CJ, et al. Among authors: yamaguchi k. Acta Neuropathol. 2023 May;145(5):573-595. doi: 10.1007/s00401-023-02555-3. Epub 2023 Mar 20. Acta Neuropathol. 2023. PMID: 36939875 Free PMC article.
Large-Scale Chromatin Rearrangements in Cancer.
Yamaguchi K, Chen X, Oji A, Hiratani I, Defossez PA. Yamaguchi K, et al. Cancers (Basel). 2022 May 12;14(10):2384. doi: 10.3390/cancers14102384. Cancers (Basel). 2022. PMID: 35625988 Free PMC article. Review.
Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study.
Yanase T, Tsuruta N, Yamaguchi K, Ohata C, Ohyama B, Katayama E, Sugita K, Kuwashiro M, Hashimoto A, Yonekura K, Higashi Y, Murota H, Koike Y, Matsuzaka Y, Kikuchi S, Hatano Y, Saito K, Takahashi K, Miyagi T, Kaneko S, Ota M, Harada K, Morizane S, Ikeda K, Furue M, Nakahara T, Okazaki F, Sasaki N, Okada E, Yoshida Y, Ito K, Imafuku S. Yanase T, et al. Among authors: yamaguchi k. J Dermatol. 2023 Jun;50(6):753-765. doi: 10.1111/1346-8138.16737. Epub 2023 Feb 14. J Dermatol. 2023. PMID: 36786158
7,328 results